PI: Prof. Laura Ottini

Funded by: Italian Association for Cancer Research (Fondazione AIRC)

Timeframe: 5-year project (2023-2028)

Male breast cancer (MBC) is a rare and biologically distinct disease that has traditionally been managed using evidence derived from female breast cancer. This has led to delayed diagnosis, suboptimal treatment strategies, and unmet clinical needs for male patients. Addressing sex-specific differences in breast cancer is therefore a critical priority in the context of precision oncology.

This project aims to provide a comprehensive genetic and molecular characterization of MBC to better understand its underlying biology. By identifying clinically relevant biomarkers and therapeutic targets, the study will support the development of sex-specific risk assessment tools, personalized screening strategies, and targeted treatments. The goal is to improve precision, equity, and effectiveness in the clinical management of MBC.

PI: Prof. Valentina Silvestri

Funded by: Italian Association for Cancer Research (Fondazione AIRC)

Timeframe: 5-year project (2024-2029)

In recent years, several significant differences have emerged between the BRCA1 and BRCA2 genes, both associated with the hereditary risk of developing breast and ovarian cancer. The spectrum of tumors linked to BRCA2—the less thoroughly studied of the two mutations—is more heterogeneous than that associated with BRCA1. It also includes cancers in non-reproductive organs, such as the pancreas.

The aim of the project is to analyze the molecular characteristics of tumors arising in patients with BRCA2 mutations, with particular attention to gene–environment interactions and potential gender differences. The results will lead to a deeper understanding of the specific role of BRCA2 in cancer, helping to support the development of more precise, targeted, inclusive, and effective clinical strategies.

PI: Prof. Laura Ottini

Funded by: Ministry of University and Research (PRIN2022)

Timeframe: 2-year project (2023-2026)

Germline variants in cancer susceptibility genes can significantly influence an individual’s risk of developing pancreatic cancer (PC), particularly in people with a familial predisposition. While existing research has largely concentrated on the therapeutic relevance of selected genes, limited attention has been given to preventive strategies for high-risk but unaffected individuals. This project focuses on the role of germline genetic variants in PC, with the goal of advancing precision medicine approaches for both cancer prevention and treatment. 

By building on established expertise, collaborative networks, and available resources, the project aims to support early identification of at-risk individuals and contribute to the development of novel, germline-driven therapeutic opportunities. Pancreatic cancer is used as a “sentinel” disease to better understand hereditary cancer syndromes, with the ultimate objective of improving precision prevention and delivering long-term benefits for patients, and families. 

PI: Prof. Laura Ottini

Funded by: PNNR - PE 6 FONDAZIONE HEAL ITALIA

Timeframe:  2-years project  (2023-2026)

Cancer risk prediction in the Italian population is a major challenge and a key step toward precision medicine. This project aims to develop a new, integrated method for predicting cancer risk in the Italian population by combining genomic data with environmental and metabolic factors.

Key goals include refining genetic models of cancer susceptibility, adapting polygenic risk score (PRS) models for Italy, and creating tools that merge genetic and environmental risk assessments.